American Well (AMWL) 10-Q 13 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Oct. 30, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001393584
Entity Registrant Name	American Well Corp
Trading Symbol	AMWL
Document Period End Date	Sep. 30, 2020
Entity Emerging Growth Company	true
Current Fiscal Year End Date	--12-31
Entity Ex Transition Period	false
Entity Small Business	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Title of 12(b) Security	Class A common stock, par value of $0.01 per share
Security Exchange Name	NYSE
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Address, State or Province	MA
Common Class A [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		199,891,685
Common Class B [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		29,508,844
Common Class C [Member]
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		5,555,555

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 956,417	$ 137,673
Investments	129,914	39,953
Restricted cash	300
Accounts receivable ($1,408 and $2,601 from related parties and net of allowances of $1,333 and $686, respectively)	39,962	32,730
Inventories	7,775	3,104
Deferred contract acquisition costs	865	1,130
Prepaid expenses and other current assets	8,408	8,937
Total current assets	1,143,641	223,527
Restricted cash	795	1,143
Property and equipment, net	4,352	2,664
Goodwill	193,877	193,877
Intangible assets, net	57,718	63,535
Operating lease right-of-use asset	8,201	11,944
Deferred contract acquisition costs, net of current portion	2,627	1,639
Other assets	1,126	1,552
Investment in minority owned joint venture	1,690
Total assets	1,414,027	499,881
Current liabilities:
Accounts payable	7,670	6,504
Accrued expenses and other current liabilities	38,301	27,351
Operating lease liability, current	6,321	6,232
Deferred revenue ($6,325 and $12,912 from related parties, respectively)	54,324	66,490
Total current liabilities	106,616	106,577
Other long-term liabilities	115	309
Operating lease liability, net of current portion	3,056	7,164
Deferred revenue, net of current portion ($275 and $1,385 from related parties, respectively)	7,480	10,896
Total liabilities	117,267	124,946
Commitments and contingencies (Note 12)
Convertible preferred stock, $0.01 par value; no shares authorized, issued or outstanding as of September 30, 2020, and 17,744,445 shares authorized 14,061,508 shares issued and 14,012,935 shares outstanding as of December 31, 2019; aggregate liquidation preference of $0 and $608,449, respectively		655,799
Stockholders' deficit:
Preferred stock, $0.01 par value; 100,000,000 shares authorized, no shares issued or outstanding as of September 30, 2020, and no shares authorized, issued or outstanding as of December 31, 2019
Common stock, $0.01 par value; 1,000,000,000 Class A shares authorized, 200,131,318 shares issued and 199,647,646 shares outstanding, 100,000,000 Class B shares authorized, 29,950,326 shares issued and 29,032,042 shares outstanding, 200,000,000 Class C shares authorized 5,555,555 issued and outstanding as of September 30, 2020; and 220,000,000 common stock shares authorized, 42,338,679 shares issued and 42,302,845 shares outstanding as of December 31, 2019	2,343	423
Treasury stock, 1,401,956 shares and 35,834 shares as of September 30, 2020 and as of December 31, 2019, respectively	(24,320)	(158)
Additional paid-in capital	1,828,395	50,289
Accumulated other comprehensive income	50	250
Accumulated deficit	(532,047)	(357,927)
Total American Well Corporation stockholders' equity (deficit)	1,274,421	(307,123)
Non-controlling interest	22,339	26,259
Total stockholders' equity (deficit)	1,296,760	(280,864)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 1,414,027	$ 499,881

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable from related parties	$ 1,408	$ 2,601
Accounts receivable net of allowances	1,333	686
Deferred revenue from related parties current	6,325	12,912
Deferred revenue from related parties non current	$ 275	$ 1,385
Convertible Preferred stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Convertible Preferred stock, Shares Authorized	0	17,744,445
Convertible Preferred stock, Shares Issued	0	14,061,508
Convertible Preferred stock, Shares Outstanding	0	14,012,935
Convertible Preferred stock, Liquidation Preference	$ 0	$ 608,449
Preferred Stock, Par Value	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	100,000,000	0
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	1,300,000,000
Common Stock, Shares, Issued	235,637,199
Common Stock, Shares, Outstanding	234,235,243
Treasury Stock, Shares	1,401,956	35,834
Common Class A [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares, Issued	200,131,318	200,131,318
Common Stock, Shares, Outstanding	199,647,646	199,647,646
Common Class B [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	29,950,326	29,950,326
Common Stock, Shares, Outstanding	29,032,042	29,032,042
Common Class C [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	5,555,555	5,555,555
Common Stock, Shares, Outstanding	5,555,555	5,555,555
Common Stock [Member]
Common Stock, Par Value	$ 0.01	$ 0.01
Common Stock, Shares Authorized	220,000,000	220,000,000
Common Stock, Shares, Issued	42,338,679	42,338,679
Common Stock, Shares, Outstanding	42,302,845	42,302,845

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations And Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
($14,868, $8,253, $44,028 and $24,404 from related parties, respectively)	$ 62,551	$ 34,744	$ 184,833	$ 103,825
Costs and operating expenses:
Costs of revenue, excluding depreciation and amortization of intangible assets	42,116	19,060	118,969	55,060
Research and development	25,275	13,602	57,848	39,169
Sales and marketing	13,758	11,309	39,978	33,951
General and administrative	43,113	14,654	138,537	40,189
Depreciation and amortization expense	2,576	1,868	7,371	5,668
Total costs and operating expenses	126,838	60,493	362,703	174,037
Loss from operations	(64,287)	(25,749)	(177,870)	(70,212)
Interest income and other income (expense), net	255	1,286	1,410	4,547
Loss before benefit (expense) from income taxes and loss from equity method investment	(64,032)	(24,463)	(176,460)	(65,665)
Benefit (expense) from income taxes	(78)	392	(330)	22
Loss from equity method investment	(486)		(1,250)
Net loss	(64,596)	(24,071)	(178,040)	(65,643)
Net loss attributable to non-controlling interest	(1,515)	(56)	(3,920)	(884)
Net loss attributable to American Well Corporation	$ (63,081)	$ (24,015)	$ (174,120)	$ (64,759)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.92)	$ (0.57)	$ (3.38)	$ (1.55)
Weighted-average common shares outstanding, basic and diluted	68,499,106	41,933,597	51,492,988	41,805,929
Net loss	$ (64,596)	$ (24,071)	$ (178,040)	$ (65,643)
Other comprehensive loss, net of tax:
Unrealized loss on available-for-sale investments	(135)	(226)	(415)	(938)
Foreign currency translation	37	(59)	215	(188)
Comprehensive loss	(64,694)	(24,356)	(178,240)	(66,769)
Less: Comprehensive loss attributable to non-controlling interest	(1,515)	(56)	(3,920)	(884)
Comprehensive loss attributable to American Well Corporation	$ (63,179)	$ (24,300)	$ (174,320)	$ (65,885)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations And Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue from Related Parties	$ 14,868	$ 8,253	$ 44,028	$ 24,404

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stock Holder's Equity Deficit - USD ($) $ in Thousands	Total	Convertible Preferred Stock [Member]	Common Stock, Class A, Class B and Class C [Member]	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Equity (Deficit) [Member]	American Well Corporation Stockholder Equity (Deficit) [Member]	Noncontrolling Interest [Member]
Beginning balance at Dec. 31, 2018		$ 575,713	$ 414		$ 37,127	$ 1,351	$ (270,737)	$ (231,845)	$ 27,435
Beginning balance at Dec. 31, 2018	$ (204,410)
Beginning balance (in shares) at Dec. 31, 2018		12,927,549	41,393,622
Exercise of common stock options	361		$ 4		357			361
Exercise of common stock options, Shares			443,846
Stock-based compensation expense	2,600				2,600			2,600
Currency translation adjustment	(49)					(49)		(49)
Unrealized loss on available-for-sale securities, net of tax	(333)					(333)		(333)
Net loss	(21,515)						(21,131)	(21,131)	(384)
Ending balance at Mar. 31, 2019		$ 575,713	$ 418		40,084	969	(291,868)	(250,397)	27,051
Ending balance at Mar. 31, 2019	(223,346)
Ending balance, Shares at Mar. 31, 2019		12,927,549	41,837,468
Beginning balance at Dec. 31, 2018		$ 575,713	$ 414		37,127	1,351	(270,737)	(231,845)	27,435
Beginning balance at Dec. 31, 2018	(204,410)
Beginning balance (in shares) at Dec. 31, 2018		12,927,549	41,393,622
Treasury stock at Sep. 30, 2019	(158)			$ (158)				(158)
Treasury Stock, Shares at Sep. 30, 2019			(35,834)
Currency translation adjustment	(188)
Unrealized loss on available-for-sale securities, net of tax	(938)
Net loss	(65,643)
Ending balance at Sep. 30, 2019		$ 575,713	$ 420	(158)	46,406	225	(335,496)	(288,603)	26,551
Ending balance at Sep. 30, 2019	(262,052)
Ending balance, Shares at Sep. 30, 2019		12,927,549	42,035,795
Beginning balance at Dec. 31, 2018		$ 575,713	$ 414		37,127	1,351	(270,737)	(231,845)	27,435
Beginning balance at Dec. 31, 2018	(204,410)
Beginning balance (in shares) at Dec. 31, 2018		12,927,549	41,393,622
Treasury stock at Dec. 31, 2019	$ (158)
Treasury Stock, Shares at Dec. 31, 2019	(35,834)
Ending balance at Dec. 31, 2019	$ (307,123)	$ 655,799	$ 423	(158)	50,289	250	(357,927)	(307,123)	26,259
Ending balance at Dec. 31, 2019	(280,864)
Ending balance, Shares at Dec. 31, 2019		14,012,935	42,302,845
Beginning balance at Mar. 31, 2019		$ 575,713	$ 418		40,084	969	(291,868)	(250,397)	27,051
Beginning balance at Mar. 31, 2019	(223,346)
Beginning balance (in shares) at Mar. 31, 2019		12,927,549	41,837,468
Exercise of common stock options	18				18			18
Exercise of common stock options, Shares			11,546
Stock-based compensation expense	2,471				2,471			2,471
Currency translation adjustment	(80)					(80)		(80)
Unrealized loss on available-for-sale securities, net of tax	(379)					(379)		(379)
Net loss	(20,057)						(19,613)	(19,613)	(444)
Ending balance at Jun. 30, 2019		$ 575,713	$ 418		42,573	510	(311,481)	(267,980)	26,607
Ending balance at Jun. 30, 2019	(241,373)
Ending balance, Shares at Jun. 30, 2019		12,927,549	41,849,014
Exercise of common stock options	230		$ 1		229			230
Exercise of common stock options, Shares			75,647
Vesting of restricted stock units	1		$ 1					1
Vesting of restricted stock units ,Shares			146,968
Treasury stock at Sep. 30, 2019	(158)			(158)				(158)
Treasury Stock, Shares at Sep. 30, 2019			(35,834)
Stock-based compensation expense	3,604				3,604			3,604
Currency translation adjustment	(59)					(59)		(59)
Unrealized loss on available-for-sale securities, net of tax	(226)					(226)		(226)
Net loss	(24,071)						(24,015)	(24,015)	(56)
Ending balance at Sep. 30, 2019		$ 575,713	$ 420	(158)	46,406	225	(335,496)	(288,603)	26,551
Ending balance at Sep. 30, 2019	(262,052)
Ending balance, Shares at Sep. 30, 2019		12,927,549	42,035,795
Beginning balance at Dec. 31, 2019	(307,123)	$ 655,799	$ 423	(158)	50,289	250	(357,927)	(307,123)	26,259
Beginning balance at Dec. 31, 2019	(280,864)
Beginning balance (in shares) at Dec. 31, 2019		14,012,935	42,302,845
Issuance of Series C convertible preferred stock, net of issuance costs		$ 12,489
Issuance of Series C convertible preferred stock, net of issuance costs,Shares		170,000
Exercise of common stock options	2				2			2
Exercise of common stock options, Shares			7,392
Vesting of restricted stock units	1		$ 1					1
Vesting of restricted stock units ,Shares			146,969
Stock-based compensation expense	4,458				4,458			4,458
Retirement of treasury stock				158	158
Currency translation adjustment	(171)					(171)		(171)
Unrealized loss on available-for-sale securities, net of tax	43					43		43
Net loss	(25,225)						(24,382)	(24,382)	(843)
Ending balance at Mar. 31, 2020		$ 668,288	$ 424		54,591	122	(382,309)	(327,172)	25,416
Ending balance at Mar. 31, 2020	(301,756)
Ending balance, Shares at Mar. 31, 2020		14,182,935	42,457,206
Beginning balance at Dec. 31, 2019	(307,123)	$ 655,799	$ 423	(158)	50,289	250	(357,927)	(307,123)	26,259
Beginning balance at Dec. 31, 2019	(280,864)
Beginning balance (in shares) at Dec. 31, 2019		14,012,935	42,302,845
Treasury stock at Sep. 30, 2020	$ (24,320)
Treasury Stock, Shares at Sep. 30, 2020	(1,401,956)
Currency translation adjustment	$ 215
Unrealized loss on available-for-sale securities, net of tax	(415)
Net loss	(178,040)
Ending balance at Sep. 30, 2020	1,274,421		$ 2,343	(24,320)	1,828,395	50	(532,047)	1,274,421	22,339
Ending balance at Sep. 30, 2020	1,296,760
Ending balance, Shares at Sep. 30, 2020			234,235,243
Beginning balance at Mar. 31, 2020		$ 668,288	$ 424		54,591	122	(382,309)	(327,172)	25,416
Beginning balance at Mar. 31, 2020	(301,756)
Beginning balance (in shares) at Mar. 31, 2020		14,182,935	42,457,206
Issuance of Series C convertible preferred stock, net of issuance costs		$ 133,525
Issuance of Series C convertible preferred stock, net of issuance costs,Shares		1,342,750
Exercise of common stock options	2,327		$ 8		2,319			2,327
Exercise of common stock options, Shares			768,106
Vesting of restricted stock units	2		$ 2					2
Vesting of restricted stock units ,Shares			204,829
Treasury stock at Jun. 30, 2020	(163)			(163)				(163)
Treasury Stock, Shares at Jun. 30, 2020			(61,600)
Stock-based compensation expense	67,638				67,638			67,638
Currency translation adjustment	349					349		349
Unrealized loss on available-for-sale securities, net of tax	(323)					(323)		(323)
Net loss	(88,219)						(86,657)	(86,657)	(1,562)
Ending balance at Jun. 30, 2020		$ 801,813	$ 434	(163)	124,548	148	(468,966)	(343,999)	23,854
Ending balance at Jun. 30, 2020	(320,145)
Ending balance, Shares at Jun. 30, 2020		15,525,685	43,368,541
Exercise of common stock options	1,886		$ 9		1,877			1,886
Exercise of common stock options, Shares			885,253
Vesting of restricted stock units			$ 34		(34)
Vesting of restricted stock units ,Shares			3,458,849
Conversion of Series A, Series B, and Series C convertible preferred stock into Class A shares	801,813	$ (801,813)	$ 1,366		800,447			801,813
Conversion of Series A, Series B, and Series C convertible preferred stock into Class A shares, Shares		(15,525,685)	136,625,900
Issuance of Class A shares in connection with initial public offering, net of offering costs and underwriting discounts of $53,730	768,537		$ 457		768,080			768,537
Issuance of Class A shares in connection with initial public offering, net of offering costs and underwriting discounts of $53,730, Shares			45,681,499
Issuance of Class C shares in connection with Google Private Placement, net of offering costs of $900	99,100		$ 56		99,044			99,100
Issuance of Class C shares in connection with Google Private Placement, net of offering costs of $900, Shares			5,555,555
Class A and Class B shares withheld related to net share settlement of loans	(24,157)		$ (13)	(24,157)	13			(24,157)
Class A and Class B shares withheld related to net share settlement of loans, Shares			(1,340,354)
Treasury stock at Sep. 30, 2020	$ (24,320)
Treasury Stock, Shares at Sep. 30, 2020	(1,401,956)
Stock-based compensation expense	$ 34,420				34,420			34,420
Currency translation adjustment	37					37		37
Unrealized loss on available-for-sale securities, net of tax	(135)					(135)		(135)
Net loss	(64,596)						(63,081)	(63,081)	(1,515)
Ending balance at Sep. 30, 2020	1,274,421		$ 2,343	$ (24,320)	$ 1,828,395	$ 50	$ (532,047)	$ 1,274,421	$ 22,339
Ending balance at Sep. 30, 2020	$ 1,296,760
Ending balance, Shares at Sep. 30, 2020			234,235,243

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Stock Holder's Equity Deficit (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Series C Preferred Stock [Member]
Convertible preferred stock, issuance costs		$ 750	$ 261
Common Class C [Member]
Payments of Stock Issuance Costs	$ 900
Common Class A [Member]
Offering costs and underwriting discounts	$ 53,730

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Statement of Cash Flows [Abstract]
Net loss	$ (64,596)	$ (25,225)	$ (24,071)	$ (21,515)	$ (178,040)	$ (65,643)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense					7,371	5,668
Provisions for doubtful accounts					1,236	621	$ 717
Amortization of deferred contract acquisition costs					852	797
Amortization of deferred contract fulfillment costs					510	531
Stock-based compensation expense					106,516	8,675
Loss on equity method investment	486				1,250
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable					(8,468)	11,878
Inventories					(4,671)	(500)
Deferred contract acquisition costs					(1,575)	(1,115)
Prepaid expenses and other current assets					(1)	(797)
Other assets					426	(846)
Accounts payable					(135)	13
Accrued expenses and other current liabilities					2,353	553
Other long-term liabilities					(194)	(902)
Deferred revenue					(15,364)	(25,548)
Net cash used in operating activities					(87,934)	(66,615)
Cash flows from investing activities:
Purchases of property and equipment					(3,261)	(1,098)
Investment in minority owned joint venture					(2,940)
Purchases of investments					(159,608)	(78,946)
Proceeds from sales and maturities of investments					69,132	226,509
Net cash (used in) provided by investing activities					(96,677)	146,465
Cash flows from financing activities:
Proceeds from issuance of Series C convertible preferred stock, net of issuance costs					146,014
Proceeds from exercise of common stock options					4,235	610
Payments for the purchase of treasury stock					(18,417)	(158)
Proceeds from issuance of common stock in initial public offering, net of underwriting costs and commissions					772,931
Proceeds from issuance of common stock to Google					100,000
Payment of deferred offering costs					(1,456)
Net cash provided by financing activities					1,003,307	452
Net increase in cash, cash equivalents, and restricted cash					818,696	80,302
Cash, cash equivalents, and restricted cash at beginning of period		138,816		54,070	138,816	54,070	54,070
Cash, cash equivalents, and restricted cash at end of period	957,512		134,372		957,512	134,372	138,816
Cash, cash equivalents, and restricted cash at end of period:
Cash and cash equivalents	956,417		133,277		956,417	133,277	137,673
Restricted cash	1,095		1,095		1,095	1,095
Total cash, cash equivalents, and restricted cash at end of period	$ 957,512	$ 138,816	$ 134,372	$ 54,070	957,512	$ 134,372	$ 54,070
Supplemental disclosure of cash flow information:
Cash paid for income taxes					138
Supplemental disclosure of non-cash investing and financing activities:
Additions to property and equipment included in accrued expenses and accounts payable					19
Initial public offering and Google common stock offering costs in accrued expenses					3,838
Treasury stock costs in accrued expenses					$ 5,903

Organization and Description of

Organization and Description of Business	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Description of Business American Well Corporation (the “Company”) was incorporated under the laws of the State of Delaware in June 2006. The Company is headquartered in Boston, Massachusetts. The Company is a leading telehealth company that enables the digital distribution and delivery of care for healthcare’s key stakeholders. The Company’s scalable technology is deployed at the enterprise level of clients, embeds into existing offerings and workflows, spans the continuum of care and enables the delivery of this care across a wide variety of clinical, retail, school and home settings. The Company is subject to a number of risks similar to other companies of a similar size in the high technology industry, including, but not limited to, uncertainty of progress in developing technologies, new technological innovations, dependence on key personnel, protection of proprietary technology, uncertainty of market acceptance of telehealth and the need for additional financing. Initial Public Offering On September 21, 2020, the Company closed on its initial public offering (the “IPO”) in which the Company issued and sold 45,681,499 shares of Class A costs , the shares of Class A common Google Private Placement On August 22, 2020, the Company entered into a strategic partnership and stock purchase agreement with Google LLC, where the Company agreed to issue Google $100,000 of Class C common stock, with the price per share to be equal to the purchase price in the IPO. Concurrently with the IPO, the Company consummated the private placement offering to Google and issued Google 5,555,555 shares of Class C common stock for $ 99,100 after deducting offering costs of $900. Stock Split On August 28, 2020 the Company effected an 8.8-for-1.0 the Company’s the n Liquidity and Capital Resources The accompanying condensed consolidated in gross proceeds. The the next twelve months .

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies There have been no material changes to the significant accounting policies described in the Company’s final prospectus, as amended, filed on September 18, 2020 with the SEC pursuant to Rule 424(b) under the Securities Act of 1933 (the “Prospectus”) during the nine months ended September 30, 2020. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and nine months ended September 30, 2020 are not necessarily indicative of results for the full 2020 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Prospectus. The unaudited condensed For substantially all of the Company’s subsidiaries the functional currency is the U.S. dollar. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net income (loss) attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets. Use of Estimates The preparation of condensed condensed condensed Due to the COVID-19 COVID-19 COVID-19 Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented. Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed The aggregate carrying value of total assets and total liabilities included on the condensed Total revenue included on the condensed income condensed 12,258 and $ 3,562 for the three months ended September 30, 2020 and 2019, respectively. Total revenue included on the condensed condensed Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, During the nine months ended September 30, 2020, the Company contributed $2,940 as its initial investment for a 49% interest in CCA W Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of September 30, 2020 and December 31, 2019, no customer accounted for 10% or greater of outstanding accounts receivable. During the three and nine months ended September 30, 2020, sales to one related party customer represented 22% of the Company’s total revenue, for both periods Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement 2018-13’’), 2018-13 2018-13 condensed In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use 350-40): Arrangement That Is a Service Contract internal-use-software. condensed Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13’’), 2016-13 available-for-sale No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses non-public 2016-13. No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief 2019-05’’). 2019-05 2016-13 2016-13 2016-13 condensed In December 2019, the FASB issued ASU 2019-12, 2019-12”), 2019-12 2019-12 condensed

Revenue

Revenue	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Platform subscription $ 25,834 $ 21,959 $ 72,048 $ 60,849 Visits 28,455 7,177 90,936 25,681 Other 8,262 5,608 21,849 17,295 Total Revenue $ 62,551 $ 34,744 $ 184,833 $ 103,825 Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for doubtful accounts, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off non-recovery condensed Changes in the allowance for doubtful accounts were as follows: Nine Months Ended Year Ended Allowance for doubtful accounts, beginning of the period $ 686 $ 396 Provisions 1,236 717 Write-offs (589 ) (427 ) Allowance for doubtful accounts, end of the period $ 1,333 $ 686 The Company has rights to consideration for services completed but not billed at the reporting date. Unbilled receivables are classified as receivables when the Company has the right to invoice the customer. The amount of unbilled accounts receivable was $3,294 and $1,622 as of September 30, 2020 and December 31, 2019, and has been included within accounts receivable on the condensed Deferred Revenue Contract liabilities consist of deferred revenue and include billings in advance of performance under the contract. Such amounts are recognized as revenue over the contractual period. For the three and nine-months ended September 30, 2020, the Company recognized revenue of $43,656 and $61,775, respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. For the three and nine-months ended September 30, 2019, the Company recognized revenue of $25,229 and $57,128 respectively, that was included in the corresponding contract liability balance at the beginning of the periods presented. Significant changes in the Company’s deferred revenue balance for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows: Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Total deferred revenue, beginning of the period $ 77,386 $ 93,299 Additions 56,825 85,167 Recognized (72,407 ) (101,080 ) Total deferred revenue, end of the period $ 61,804 $ 77,386 September 30, 2020 December 31, 2019 Current deferred revenue 54,324 66,490 Non-current 7,480 10,896 Total deferred revenue, end of the period $ 61,804 $ 77,386 Transaction Price Allocated to Remaining Performance Obligations As of September 30, 2020 and December 31, 2019, the aggregate amount of the transaction price allocated to remaining performance obligations was $170,168 and $162,230, respectively. The substantial majority of the unsatisfied performance obligations will be satisfied over the next three years. As it pertains to the December 31, 2019 amount, the Company expects to recognize 45% of the transaction price in the year ending December 31, 2020 in its condensed condensed

National Telehealth Network

National Telehealth Network	9 Months Ended
	Sep. 30, 2020
Equity Method Investments and Joint Ventures [Abstract]
National Telehealth Network	4. National Telehealth Network In 2012, the Company and an affiliate of Anthem, Inc. formed NTN to expand the availability and adoption of telemedicine. The Company did not have a controlling financial interest in NTN, but it had the ability to exercise significance influence over the operating and financial policies of NTN. Therefore, the Company accounted for its investment in NTN using the equity method of accounting through December 31, 2015. On January 1, 2016, the Company made an additional investment in NTN, which increased its ownership percentage above 50%. The Company also obtained the right to elect the Chairman of NTN , tie-breaking condensed non-controlling condensed non-controlling The proportionate share of the income (loss) attributed to the non-controlling non-controlling non-controlling

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: • Level 1—Quoted prices in active markets for identical assets or liabilities. • Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. • Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: September 30, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 52,955 $ — $ — $ 52,955 Investments — 129,914 — 129,914 52,955 129,914 — $ 182,869 December 31, 2019 Level 1 Level 2 Level 3 Total Money market funds $ 62,113 $ — $ — $ 62,113 Investments — 39,953 — $ 39,953 62,113 39,953 — 102,066 The Company’s cash equivalents were invested in money market funds and were valued based on Level 1 inputs. The Company’s investments consisted of U.S. government agency bonds and were valued based on Level 2 inputs. In determining the fair value of its U.S. government agency bonds, the Company relied on quoted prices for similar securities in active markets or other inputs that are observable or can be corroborated by observable market data. During the nine months ended September 30, 2020, there were no transfers between fair value measurement levels.

Investments

Investments	9 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Investments	6. Investments As of September 30, 2020 and December 31, 2019, the fair value of the Company’s investments by type of security was as follows: September 30, 2020 Amortized Gross Gross Fair Value Assets: U.S government securities $ 129,831 $ 83 $ — $ 129,914 129,831 83 — 129,914 December 31, 2019 Amortized Gross Gross Fair Value Assets: U.S government securities $ 39,355 $ 598 $ — $ 39,953 39,355 598 — 39,953

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Business Combinations	7. Business Combinations In November 2019, the Company acquired all the issued and outstanding shares of Aligned Telehealth, Inc. (“Aligned”). This acquisition will combine Aligned’s customer base with the Company’s telehealth platform to increase the number of hospitals and health plans utilizing telehealth. The aggregate consideration paid was $82,948, which consists of (i) 456,667 shares of the Company’s Series C convertible preferred stock valued at $34,250; (ii) $48,688 of cash and (iii) contingent consideration of $10. The Company is obligated to pay an earn-out condensed The acquisition was a stock acquisition for tax purposes and accordingly, the goodwill resulting from this acquisition is not tax deductible. The total acquisition related costs were $1,494 and recognized as general and administrative expense in the condensed condensed condensed The final Amount Cash $ 2,938 Accounts receivable 3,612 Identifiable intangible assets 14,100 Other assets 179 Total assets acquired 20,829 Current liabilities (3,102 ) Deferred tax liability (1,388 ) Total liabilities assumed (4,490 ) Goodwill 66,609 Total purchase consideration $ 82,948 The following are the identifiable intangible assets acquired and their respective weighted average useful lives, as determined based on final Amount Weighted Customer relationships $ 13,800 7.0 Trade name 300 7.0 Total $ 14,100 Customer-relationship intangible assets were valued using the multi-period, excess-earnings method, a method that values the intangible asset using the present value of the after-tax

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	8. Goodwill and Intangible Assets Goodwill consisted of the following: Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Beginning Balance as of January 1 $ 193,877 $ 127,268 Goodwill acquired (Note 7) — 66,609 Ending Balance $ 193,877 $ 193,877 Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted December 31, 2019 Customer relationships $ 38,782 $ (7,416 ) $ 31,366 8.0 Contractor relationship s 535 (165 ) 370 9.0 Trade name 300 (4 ) 296 6.9 Technology 37,063 (5,560 ) 31,503 8.5 $ 76,680 $ (13,145 ) $ 63,535 Gross Accumulated Carrying Weighted September 30, 2020 Customer relationships $ 38,782 $ (10,390 ) $ 28,392 7.3 Contractor relationships 535 (195 ) 340 8.3 Trade name 300 (38 ) 262 6.1 Technology 37,063 (8,339 ) 28,724 7.8 $ 76,680 $ (18,962 ) $ 57,718 Amortization expense related to intangible assets for the three and nine months ended September 30, 2020 was $1,940 and $5,817, respectively. Amortization expense related to intangible assets for the three and nine months ended September 30, 2019 was $1,435 and $4,305, respectively. Estimated future amortization expense of the identified intangible assets as of September 30, 2020, is as follows: 2020 $ 1,938 2021 7,755 2022 7,755 2023 7,755 2024 7,755 Thereafter 24,760

Accrued Expenses And Other Curr

Accrued Expenses And Other Current Liabilities	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
Accrued Expenses	9. Accrued Expenses and other current liabilities Accrued expenses and other current liabilities September 30, 2020 December 31, 2019 Employee compensation, benefits, and payroll taxes $ 18,133 $ 11,698 Professional services 3,805 3,351 Provider services 4,043 2,709 Transaction costs 2,518 — Other 9,802 9,593 Total $ 38,301 $ 27,351

Line of Credit

Line of Credit	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Line of Credit	10. Line of Credit In January 2011, the Company entered into a credit agreement (the “Line of Credit”) with a financial institution that provides for maximum borrowings in one or more advances of an amount up to $5,000. Borrowings under the Line of Credit accrue interest at the London Interbank Offered Rate plus 1.25%. Borrowings are repayable immediately upon demand by the financial institution. In November 2017, the Line of Credit was amended to increase the maximum borrowings to $7,000. As of September 30, 2020 and December 31, 2019, the Company had no outstanding borrowings under the Line of Credit. During any period that the Line of Credit is in effect, the Company can request the financial institution issue a letter of credit with a maximum maturity not to exceed twelve months. Any letters of credit issued by the financial institution was

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	11. Stockholders’ Equity Convertible Preferred Stock The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Shares Shares Liquidation Carrying Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799 In the year ended December 31, 2019, the Company issued and sold 628,719 shares of Series C preferred stock at a price of $75 per share for gross proceeds of $47,154. The Company incurred $1,318 of issuance costs in connection with the issuance of the Series C preferred stock. Additionally, the Company issued 456,667 shares of Series C preferred stock at a price of $75 per share in connection with the acquisition of Aligned (see Note 7). In February 2020, the Company issued and sold 170,000 shares of Series C preferred stock at a price of $75 per share for gross proceeds of $12,750. The Company incurred $261 of issuance costs in connection with the issuance of the Series C preferred stock In May 2020, the Company issued and sold 1,342,750 shares of Series C preferred stock at a price of $100 per share for gross proceeds of $134,275. The Company incurred $750 of issuance costs in connection with the issuance of the Series C preferred stock. In conjunction with the Company’s IPO in September 2020, all shares of convertible preferred stock then outstanding, totaling 15,525,685 shares (pre-split), an equivalent number of 8.8-to-1.0 In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes the issuance of 100,000,000 shares of undesignated preferred stock, par value of $0.01 per share, with rights and preferences, including voting rights, designated from time to time by the board of directors. Common Stock In September 2020, upon completion of the IPO, the Company sold 45,681,499 shares of Class A common stock at an offering price of $18.00 per share, including 4,459,277 shares of Class A , for net proceeds of , after deducting offering costs of $900. Concurrently with the IPO , shares of Class A and Class B common stock from certain executive officers and other employees, to permit such executive officers and other employees to pay taxes owed in connection with the vesting of equity awards, including the repayment of third party loans incurred to finance the payment of such taxes. In connection with the IPO, the Company filed an Amended and Restated Certificate of Incorporation which authorizes capital stock of 1,000,000,000 shares of Class A common stock, par value $0.01 per share, 100,000,000 shares of Class B common stock, par value $0.01 per share, and 200,000,000 shares of Class C common stock, par value $0.01 per share. Except for the rights noted below , is does is and each share of Class B common stock will be entitled to a number of votes equal to the total number of votes held by all Class B common stock divided by the total number of then outstanding shares of Class B common stock. Shares of Class B and Class C common stock will be converted into shares of Class A common stock on a one-for-one basis upon the occurrence of certain events. Shares of Class B common stock will automatically convert on the first business day (i) after the date on which the outstanding shares of Class B common stock constitutes less than 5% of the aggregate number of shares of common stock then outstanding, (ii) after the date on which neither founder is serving as an executive officer or As of September 30, 2020 the par value of the Class A, Class B and Class C shares was $1,997, $290, and $56, respectively. Shares Shares Issued Shares Class A 1,000,000,000 200,131,318 199,647,646 Class B 100,000,000 29,950,326 29,032,042 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 235,637,199 234,235,243 As of September 30, 2020, the Company had reserved 63,226,337 shares of common stock for the exercise of outstanding stock options, the vesting of restricted stock units and the number of shares remaining available for future grant. As of December 31, 2019, the Company had reserved 157,998,948 shares of common stock for the conversion of the outstanding shares of Preferred Stock, the exercise of outstanding stock options, the vesting of restricted stock units and the number of shares remaining available for future grant. Stock Plans and Stock Options The Company maintains the 2006 Employee, Director and Consultant Stock Plan as amended and restated (the “2006 Plan”) and 2020 Equity Incentive Plan (the “2020 Plan” together, the “Plans”) under which it has granted incentive stock options, non-qualified non-employee The 2020 Plan became effective on shares of Class A and Class B common stock were initially reserved for issuance pursuant to the 2020 Plan, which number was increased to 31,275,204 shares immediately following the IPO The Company had 27,614,753 shares available for grant as of September 30, 2020. Options issued under the Plans are exercisable for periods not to exceed ten years, and vest and contain such other terms and conditions as specified in the applicable award document. Options to buy common stock are issued under the Plans, with exercise prices equal to the closing price of shares of the Company’s common stock on the New York Stock Exchange on the date of award. Activity under the Plans is as follows: Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2019 24,917,003 $ 3.90 6.9 $ 79,798 Granted 2,637,220 $ 7.80 Forfeited (1,697,171 ) $ 4.80 Expired (132,001 ) $ 2.16 Exercised (1,660,751 ) $ 2.59 Outstanding as of September 30, 2020 24,064,300 $ 4.35 6.4 $ 610,782 Vested and expected to vest as of December 31, 2019 22,650,355 $ 3.73 6.7 $ 76,321 Vested and expected to vest as of September 30, 2020 22,212,804 $ 4.09 6.2 $ 567,533 Options exercisable as of December 31, 2019 14,685,654 $ 2.83 5.5 $ 62,869 Options exercisable as of September 30, 2020 16,254,829 $ 3.43 5.3 $ 426,049 The weighted-average grant date fair value of common stock options granted during the three months ended September 30, 2020 was $ 5.06 . No 4.17 2.78 12,688 Executive Equity Awards In the second quarter of 2020, the Company entered into employment agreements with the Company’s two Chief Executive Officers. Each agreement provided a restricted stock units, totaling 5,721,760 restricted stock units. The restricted stock unit grants of 2,860,880 units to each CEO, have no future service period in order to vest and therefore the Company recognized $56,971, the full amount of stock-based compensation expense, in the second quarter of 2020. The employment agreements modified the that had been previously issued, 1,764,884 options each , the In addition, each CEO has received, and will receive additional restricted stock units, equaling up to % of the Company’s fully-diluted outstanding capital stock as a result of the IPO (“IPO RSUs”), 50% of the IPO RSUs (representing 0.75% of the Company’s fully diluted outstanding capital stock immediately prior to the IPO or 3,230,750 shares of Class A common stock) were granted on the closing date of the IPO based on the closing price per share on the IPO closing date, and 50% (representing up to immediately prior to the IPO ) March 16 The grant-date fair value of each of the awards issued on the IPO closing date and to be issued on the 180-day anniversary of the IPO was estimated using a binomial lattice approach. The main inputs to valuing the IPO RSUs include the fair value of Class A common stock ($9.96 post-split $23,644 stock-based compensation expense, which included both tranches of the IPO RSU for each CEO, on the date of the IPO as the requisite future service of the awards is not substantive for accounting purposes. Restricted Stock Units During the year four years four years Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of December 31, 2019 2,322,408 $ 5.79 Granted 13,039,392 13.41 Vested (3,810,645 ) 9.50 Forfeited (3,871 ) 10.79 Unvested as of September 30, 20 2 11,547,284 $ 13.17 The amount of compensation costs recognized for the three months ended September 30, 2020 and 2019 on the restricted stock units expected to vest was $31,253 and $1,297, respectively. The amount of compensation costs recognized for the nine months ended September 30, 2020 and 2019 on the restricted stock units expected to vest was $91,168 and $1,297, respectively. As of September 30, 2020, the unrecognized stock-based compensation expense related to these restricted awards was $39,449, which is expected to be recognized over a weighted-average period of 3.0 years. Stock-Based Compensation The weighted average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Nine Month Ended 2020 2019 Risk-free interest rate 1.09 % 2.44 % Expected term (in years) 6.1 6.1 Expected volatility 52 % 50 % Expected dividend yield 0 % 0 % Stock-based compensation expense was classified in the condensed Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 309 $ 124 $ 668 $ 360 Research and development 2,083 360 3,519 1,169 Selling and marketing 1,138 540 2,684 1,848 General and administrative 30,890 2,580 99,645 5,298 Total $ 34,420 $ 3,604 $ 106,516 $ 8,675 2020 Employee Stock Purchase Plan In July and August 2020, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2020 Employee Stock Purchase Plan (“ESPP”). A total of 3,084,218 shares of Class A common stock were reserved for issuance under the ESPP. The ESPP is expected to become effective January 1, 2021. Rights granted under the ESPP will be issued only with respect to shares of Class A common stock. Subject to any limitations contained therein, under the ESPP an employee will be permitted to accrue the right to purchase stock under the ESPP up to $25,000 worth of shares during any calendar year. The purchase price of the shares will not be less than 85% of the fair market value of Class A common stock on the lower of the purchase date, which will be the final trading day of the purchase period, or the enrollment date, which will be the first trading day of the offering period.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Indemnification The Company’s arrangements generally include certain provisions for indemnifying customers against third-party claims asserting infringement of certain intellectual property rights in the ordinary course of business. The Company also regularly indemnifies customers against third-party claims that the company’s products or services breach applicable law or regulation or from claims resulting from a breach of the business associate agreement in place with the customer. In addition, the Company indemnifies its officers, directors and certain key employees while they are serving in good faith in their capacities. Through September 30, 2020 and December 31, 2019, there have been no claims under any indemnification provisions. Litigation From time to time, and in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. On September 14, 2020, the Company received a letter from Teladoc Health, Inc. alleging that certain of the Company’s cart products and associated peripherals infringe upon their patents. On October 12, 2020, Teladoc Health, Inc filed a claim against the Company related to these allegations. The Company believes that these claims lack merit and intends to defend against them vigorously. As of September 30, 2020 and December 31, 2019, the Company did have any pending claims, charges or litigation that it expects would have a material adverse effect on its consolidated financial position, results of operations or cash flows.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes As a result of the Company’s history of net operating losses (“NOL”), the Company has provided for a full valuation allowance against its deferred tax assets. For the three and nine months ended September 30, 2020, the Company recognized an income tax expense of $78 and $330, respectively, primarily due to the amortization of acquired intangibles and stock compensation deductions. For the three months and nine months ended September 30, 2019, the Company recognized an income tax benefit of $392 and $22, respectively, related to certain United States and foreign income, as well as amortization of tax-deductible

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	14. Related-Party Transactions Teva Pharmaceuticals, Industries Ltd Teva Pharmaceuticals, Industries Ltd (“Teva”) is a related party because a member of the Company’s board of directors is the Executive Vice President and Head of Teva Pharmaceuticals’ North America Commercial. In addition, Teva is a shareholder of the Company. As of September 30, 2020 and December 31, 2019, short-term and long-term deferred revenue from this customer was not material. As of September 30, 2020 and December 31, 2019, there were no amounts due from Teva. During the three months ended September 30, 2020 and 2019, and the nine months ended September 30, 2020 and 2019, revenues recognized from this customer were not material. Philips Holding USA, Inc. Philips Holding USA, Inc. (“Philips”) is a related party because a member of the Company’s board of directors is the Business Leader of Philips Population Health Management. In addition, Philips is a shareholder of the Company. As of September 30, 2020 and December 31, 2019, the Company held short-term and long-term deferred revenue of $1,195 and $2,549, respectively from contracts with this customer. As of September 30, 2020 and December 31, 2019, amounts due from Philips were not material. During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $418 and $146, respectively from contracts with this customer. During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $1,126 and $372, respectively from contracts with this customer. Anthem Inc. Anthem Inc. (“Anthem”) is a related party because a member of the Company’s board of directors is a Vice President of Anthem. In addition, Anthem is a shareholder of the Company. As of September 30, 2020 and December 31, 2019, the Company held short-term and long-term deferred revenue of $4,671 and $11,561, respectively from contracts with this customer. As of September 30, 2020 and During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $13,522 and $7,837, respectively from contracts with this customer. During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $40,677 and $23,120, respectively from contracts with this customer. Cleveland Clinic Cleveland Clinic is a related party because a member of the Company’s board of directors is an executive advisor to Cleveland Clinic. As of September 30, 2020 and December 31, 2019, the Company held short-term and long-term deferred revenue of $457 and $180, respectively from contracts with this customer. As of September 30, 2020, amounts due from Cleveland Clinic were $205. As of December 31, 2019, amounts due from Cleveland Clinic were not material. During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $514 and $262, respectively, from contracts with this customer. During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $1,004 and $889, respectively, from contracts with this customer. CCAW, JV LLC CCAW, JV LLC is a related party because it is a joint venture formed between the Company and Cleveland Clinic for which the Company has a minority owned interest in. During the nine months ended September 30, 2020 the Company made an initial investment in CCAW, JV LLC of $2,940 for its less than 50% interest in the joint venture. During the three and nine months ended September 30, 2020 the Company recognized revenue of $404 and $1,190 from contracts with this customer, respectively. As of September 30, 2020, the Company held short and long term deferred revenue of $277 from contracts with this customer. As of September 30, 2020, amounts due from CCAW, JV LLC were not material. Loans to Officers During the year ended December 31, 2019, the Company entered into secured promissory notes with the Company’s Chief Financial Officer in the amount of . During 2020, the Company entered into additional secured promissory notes with the Chief Financial Officer and of $ . These loans were to fund the taxes associated with the restricted stock units and were collateralized by all of the capital stock of the Company that the employee owned or would own in the future and the employees’ personal assets. These loans are recorded within prepaids and other current assets in the Company’s condensed consolidated balance sheet. All outstanding loans with officers were repaid in August 2020 prior to the Company’s IPO.

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Share	15. Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended September 30, Nine Months Ended 2020 2019 2020 2019 Numerator: Net loss $ (64,596 ) $ (24,071 ) $ (178,040 ) $ (65,643 ) Net income (loss) attributable to non-controlling (1,515 ) (56 ) (3,920 ) (884 ) Net loss attributable to American Well Corporation $ (63,081 ) $ (24,015 ) $ (174,120 ) $ (64,759 ) Denominator: Weighted-average common shares outstanding—basic and diluted 68,499,106 41,933,597 51,492,988 41,805,929 Net loss per share attributable to common stockholders—basic and diluted $ (0.92 ) $ (0.57 ) $ (3.38 ) $ (1.55 ) The Company’s potential dilutive securities, which include stock options, convertible preferred stock and unvested restricted stock units, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended 2020 2019 2020 2019 Convertible preferred stock (as converted to common stock) — 113,762,320 — 113,762,320 Unvested restricted stock units 5,455,654 — 5,455,654 — Options to purchase shares of common stock 24,064,300 23,712,967 24,064,300 23,712,967 29,519,954 137,475,287 29,519,954 137,475,287

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary for the fair statement of the Company’s the financial position, results of operations and cash flows at the dates and for the periods indicated. The interim results for the three and nine months ended September 30, 2020 are not necessarily indicative of results for the full 2020 calendar year or any other future interim periods. The information included in the interim financial statements should be read in conjunction with the annual consolidated financial statements and accompanying notes included in the Prospectus. The unaudited condensed For substantially all of the Company’s subsidiaries the functional currency is the U.S. dollar. Foreign currency denominated monetary assets and liabilities are remeasured into U.S. dollars at current exchange rates and foreign currency denominated nonmonetary assets and liabilities are remeasured into U.S. dollars at historical exchange rates. Gains or losses from foreign currency remeasurement and settlements are included in interest income and other income (expense), net in the condensed For consolidated entities where American Well owns or is exposed to less than 100% of the economics, the net income (loss) attributable to noncontrolling interests is recorded in the condensed consolidated statements of operations and comprehensive loss equal to the percentage of the economic or ownership interest retained in each entity by the respective non-controlling party. The noncontrolling interests are presented as a separate component of stockholders’ deficit in the condensed consolidated balance sheets.
Use of Estimates	Use of Estimates The preparation of condensed condensed condensed Due to the COVID-19 COVID-19 COVID-19
Segment Information	Segment Information The Company’s chief operating decision makers (CODMs), its two Chief Executive Officers, review financial information presented on a consolidated basis for purposes of allocating resources and evaluating financial performance. The Company operates and manages its business as one reportable and operating segment. In addition, substantially all of the Company’s revenue and long-lived assets are attributable to operations in the United States for all periods presented.
Variable Interest Entities	Variable Interest Entities The Company evaluates its ownership, contractual and other interests in entities to determine if it has any variable interest in a variable interest entity (“VIE”). These evaluations are complex and involve judgment. If the Company determines that an entity in which it holds a contractual or ownership interest is a VIE and that the Company is the primary beneficiary, the Company consolidates such entity in its condensed The aggregate carrying value of total assets and total liabilities included on the condensed Total revenue included on the condensed income condensed 12,258 and $ 3,562 for the three months ended September 30, 2020 and 2019, respectively. Total revenue included on the condensed condensed
Investment in Minority Owned Joint Venture	Investment in Minority Owned Joint Venture The Company and Cleveland Clinic partnered to form a joint venture, under the name CCAW, JV LLC, to provide broad access to comprehensive and high acuity care services via telehealth. The Company does not have a controlling financial interest in CCAW, JV LLC, but it does have the ability to exercise significant influence over the operating and financial policies of CCAW, JV LLC. Therefore, the Company accounts for its investment in CCAW, JV LLC using the equity method of accounting. The joint venture is considered a variable interest entity under ASC 810-10, During the nine months ended September 30, 2020, the Company contributed $2,940 as its initial investment for a 49% interest in CCA W
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. The Company invests its excess cash with large financial institutions that the Company believes are of high credit quality. Cash and cash equivalents are invested in highly rated money market funds. At times the Company’s cash balances with individual banking institutions are in excess of federally insured limits. The Company’s investments are invested in U.S. government agency bonds. The Company has not experienced any losses on its deposits of cash, cash equivalents or investments. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company performs ongoing assessments and credit evaluations of its customers to assess the collectability of the accounts based on a number of factors, including past transaction experience, age of the accounts receivable, review of the invoicing terms of the contracts, and recent communication with customers. The Company has not experienced significant credit losses from its accounts receivable. As of September 30, 2020 and December 31, 2019, no customer accounted for 10% or greater of outstanding accounts receivable. During the three and nine months ended September 30, 2020, sales to one related party customer represented 22% of the Company’s total revenue, for both periods
Emerging Growth Company Status	Emerging Growth Company Status The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Requirements for Fair Value Measurement 2018-13’’), 2018-13 2018-13 condensed In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use 350-40): Arrangement That Is a Service Contract internal-use-software. condensed
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments 2016-13’’), 2016-13 available-for-sale No. 2018-19, Codification Improvements to Topic 326, Financial Instruments—Credit Losses non-public 2016-13. No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief 2019-05’’). 2019-05 2016-13 2016-13 2016-13 condensed In December 2019, the FASB issued ASU 2019-12, 2019-12”), 2019-12 2019-12 condensed
Accounts Receivable, Net	Accounts Receivable, Net Accounts receivable primarily consist of amounts billed currently due from customers. Accounts receivable are presented net of an allowance for doubtful accounts, which is an estimate of amounts that may not be collectible. In determining the amount of the allowance at each reporting date, the Company makes judgments about general economic conditions, historical write-off non-recovery condensed

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2020
Revenue from Contract with Customer [Abstract]
Summary of Disaggregation of Revenue	The following table presents the Company’s revenues disaggregated by revenue source: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Platform subscription $ 25,834 $ 21,959 $ 72,048 $ 60,849 Visits 28,455 7,177 90,936 25,681 Other 8,262 5,608 21,849 17,295 Total Revenue $ 62,551 $ 34,744 $ 184,833 $ 103,825
Summary of Changes in the Allowance for Doubtful Accounts	Changes in the allowance for doubtful accounts were as follows: Nine Months Ended Year Ended Allowance for doubtful accounts, beginning of the period $ 686 $ 396 Provisions 1,236 717 Write-offs (589 ) (427 ) Allowance for doubtful accounts, end of the period $ 1,333 $ 686
Summary of Significant Changes in the Company's Deferred Revenue	Significant changes in the Company’s deferred revenue balance for the nine months ended September 30, 2020 and the year ended December 31, 2019 were as follows: Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Total deferred revenue, beginning of the period $ 77,386 $ 93,299 Additions 56,825 85,167 Recognized (72,407 ) (101,080 ) Total deferred revenue, end of the period $ 61,804 $ 77,386
Summary of Contract with Customer Liability Current and Non Current	September 30, 2020 December 31, 2019 Current deferred revenue 54,324 66,490 Non-current 7,480 10,896 Total deferred revenue, end of the period $ 61,804 $ 77,386

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	The following tables presents the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value: September 30, 2020 Level 1 Level 2 Level 3 Total Money market funds $ 52,955 $ — $ — $ 52,955 Investments — 129,914 — 129,914 52,955 129,914 — $ 182,869 December 31, 2019 Level 1 Level 2 Level 3 Total Money market funds $ 62,113 $ — $ — $ 62,113 Investments — 39,953 — $ 39,953 62,113 39,953 — 102,066

Investments (Tables)

Investments (Tables)	9 Months Ended
	Sep. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Debt securities, available-for-sale	As of September 30, 2020 and December 31, 2019, the fair value of the Company’s investments by type of security was as follows: September 30, 2020 Amortized Gross Gross Fair Value Assets: U.S government securities $ 129,831 $ 83 $ — $ 129,914 129,831 83 — 129,914 December 31, 2019 Amortized Gross Gross Fair Value Assets: U.S government securities $ 39,355 $ 598 $ — $ 39,953 39,355 598 — 39,953

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2020
Business Combinations [Abstract]
Summary of Final Allocation of Assets Acquired and Liabilities Assumed	The final Amount Cash $ 2,938 Accounts receivable 3,612 Identifiable intangible assets 14,100 Other assets 179 Total assets acquired 20,829 Current liabilities (3,102 ) Deferred tax liability (1,388 ) Total liabilities assumed (4,490 ) Goodwill 66,609 Total purchase consideration $ 82,948
Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives	The following are the identifiable intangible assets acquired and their respective weighted average useful lives, as determined based on final Amount Weighted Customer relationships $ 13,800 7.0 Trade name 300 7.0 Total $ 14,100

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Goodwill consisted of the following: Nine Months Ended September 30, 2020 Year Ended December 31, 2019 Beginning Balance as of January 1 $ 193,877 $ 127,268 Goodwill acquired (Note 7) — 66,609 Ending Balance $ 193,877 $ 193,877
Schedule of Finite-Lived Intangible Assets	Identified intangible assets consisted of the following: Gross Accumulated Carrying Weighted December 31, 2019 Customer relationships $ 38,782 $ (7,416 ) $ 31,366 8.0 Contractor relationship s 535 (165 ) 370 9.0 Trade name 300 (4 ) 296 6.9 Technology 37,063 (5,560 ) 31,503 8.5 $ 76,680 $ (13,145 ) $ 63,535 Gross Accumulated Carrying Weighted September 30, 2020 Customer relationships $ 38,782 $ (10,390 ) $ 28,392 7.3 Contractor relationships 535 (195 ) 340 8.3 Trade name 300 (38 ) 262 6.1 Technology 37,063 (8,339 ) 28,724 7.8 $ 76,680 $ (18,962 ) $ 57,718
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future amortization expense of the identified intangible assets as of September 30, 2020, is as follows: 2020 $ 1,938 2021 7,755 2022 7,755 2023 7,755 2024 7,755 Thereafter 24,760

Accrued Expenses And Other Cu_2

Accrued Expenses And Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Payables and Accruals [Abstract]
summary of  Accrued Expenses	Accrued expenses and other current liabilities September 30, 2020 December 31, 2019 Employee compensation, benefits, and payroll taxes $ 18,133 $ 11,698 Professional services 3,805 3,351 Provider services 4,043 2,709 Transaction costs 2,518 — Other 9,802 9,593 Total $ 38,301 $ 27,351

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2020
Stockholders' Equity Note [Abstract]
Schedule of Preferred Stock by Class Not Redeemable Noncontrolling Interest	The authorized, issued and outstanding shares, liquidation preference, and carrying value of the Company’s convertible preferred stock as of December 31, 2019 were as follows: Shares Shares Shares Liquidation Carrying Series A 3,200,000 3,178,650 3,130,077 51,741 28,889 Series B 833,334 787,725 787,725 37,060 23,632 Series C 13,711,111 10,095,133 10,095,133 519,648 603,278 17,744,445 14,061,508 14,012,935 608,449 655,799
Schedule of Stock by Class	As of September 30, 2020 the par value of the Class A, Class B and Class C shares was $1,997, $290, and $56, respectively. Shares Shares Issued Shares Class A 1,000,000,000 200,131,318 199,647,646 Class B 100,000,000 29,950,326 29,032,042 Class C 200,000,000 5,555,555 5,555,555 1,300,000,000 235,637,199 234,235,243
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	Activity under the Plans is as follows: Number of Weighted Average Weighted Average Aggregate Outstanding as of December 31, 2019 24,917,003 $ 3.90 6.9 $ 79,798 Granted 2,637,220 $ 7.80 Forfeited (1,697,171 ) $ 4.80 Expired (132,001 ) $ 2.16 Exercised (1,660,751 ) $ 2.59 Outstanding as of September 30, 2020 24,064,300 $ 4.35 6.4 $ 610,782 Vested and expected to vest as of December 31, 2019 22,650,355 $ 3.73 6.7 $ 76,321 Vested and expected to vest as of September 30, 2020 22,212,804 $ 4.09 6.2 $ 567,533 Options exercisable as of December 31, 2019 14,685,654 $ 2.83 5.5 $ 62,869 Options exercisable as of September 30, 2020 16,254,829 $ 3.43 5.3 $ 426,049
Schedule of Nonvested Restricted Stock Units Activity	Activity for the restricted stock units is as follows: Shares Weighted Average Unvested as of December 31, 2019 2,322,408 $ 5.79 Granted 13,039,392 13.41 Vested (3,810,645 ) 9.50 Forfeited (3,871 ) 10.79 Unvested as of September 30, 20 2 11,547,284 $ 13.17
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average of assumptions that the Company used to determine the fair value of the common stock options granted to employees and directors were as follows: Nine Month Ended 2020 2019 Risk-free interest rate 1.09 % 2.44 % Expected term (in years) 6.1 6.1 Expected volatility 52 % 50 % Expected dividend yield 0 % 0 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Stock-based compensation expense was classified in the condensed Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019 Cost of revenues $ 309 $ 124 $ 668 $ 360 Research and development 2,083 360 3,519 1,169 Selling and marketing 1,138 540 2,684 1,848 General and administrative 30,890 2,580 99,645 5,298 Total $ 34,420 $ 3,604 $ 106,516 $ 8,675

Net Loss per Share (Tables)

Net Loss per Share (Tables)	9 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share Attributable To Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows: Three Months Ended September 30, Nine Months Ended 2020 2019 2020 2019 Numerator: Net loss $ (64,596 ) $ (24,071 ) $ (178,040 ) $ (65,643 ) Net income (loss) attributable to non-controlling (1,515 ) (56 ) (3,920 ) (884 ) Net loss attributable to American Well Corporation $ (63,081 ) $ (24,015 ) $ (174,120 ) $ (64,759 ) Denominator: Weighted-average common shares outstanding—basic and diluted 68,499,106 41,933,597 51,492,988 41,805,929 Net loss per share attributable to common stockholders—basic and diluted $ (0.92 ) $ (0.57 ) $ (3.38 ) $ (1.55 )
Summary of Antidilutive Securities Excluded From Computation of Net Loss Per Share	The Company excluded the following potential common shares equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended September 30, Nine Months Ended 2020 2019 2020 2019 Convertible preferred stock (as converted to common stock) — 113,762,320 — 113,762,320 Unvested restricted stock units 5,455,654 — 5,455,654 — Options to purchase shares of common stock 24,064,300 23,712,967 24,064,300 23,712,967 29,519,954 137,475,287 29,519,954 137,475,287

Organization and Description _2

Organization and Description of Business - Additional information (Detail) - USD ($)	Sep. 21, 2020	Aug. 28, 2020	Aug. 22, 2020	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock					$ 100,000,000
Accumulated deficit				$ (532,047,000)	(532,047,000)	$ (357,927,000)
Underwriting discounts and commissions					$ 49,336,000
Issuance of Class C shares in connection with Google Private Placement				99,100,000
Description of the stock split arrangement		8.8-for-1.0
Common Class A [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, Initial public offering					45,681,499
Net proceeds from Ipo					$ 768,537,000
Retained Earnings [member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Accumulated deficit				532,047,000	$ 532,047,000
Common Class C [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, Initial public offering					5,555,555
Issuance of Class C shares in connection with Google Private Placement			$ 100,000		$ 99,100,000
Issuance of Class C shares in connection with Google Private Placement, Shares			5,555,555
Payments of Stock Issuance Costs			$ 900,000	$ 900,000	$ 900,000
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from issuance of common stock	$ 822,267,000
IPO [Member] | Common Class A [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issue of common stocks, Initial public offering	45,681,499
Shares issued, price per share	$ 18
Net proceeds from Ipo	$ 768,537,000
Underwriting discounts and commissions	49,336,000
Other Offering Costs	$ 4,394,000
Convertible preferred stock, shares issued upon conversion	136,625,900
Private Placement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Proceeds from private placement	$ 100,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Total assets	$ 1,414,027						$ 1,414,027		$ 499,881
Total liabilities	117,267						117,267		$ 124,946
Total revenue	62,551			$ 34,744			184,833	$ 103,825
Net income loss	(64,596)	$ (88,219)	$ (25,225)	$ (24,071)	$ (20,057)	$ (21,515)	(178,040)	(65,643)
Payment to acquire interest in joint venture							2,940
Share of the net profit loss in the operations of joint venture	$ (486)						(1,250)
Consolidation, Eliminations [Member]
Summary Of Significant Accounting Policies [Line Items]
Net income loss							$ 13,267	$ 13,267
Revenue Benchmark [Member] | Related Party Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue	22.00%			23.00%			22.00%	22.00%
Minimum [Member] | Accounts Receivable [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of net total revenue							10.00%		10.00%
Consolidated Entity, Excluding VIE [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Percentage of economic or ownership interest in consolidated entities							100.00%		100.00%
Variable Interest Entity, Primary Beneficiary [Member]
Summary Of Significant Accounting Policies [Line Items]
Net income loss	$ 12,258			$ 3,562			$ 42,644	$ 42,644
Variable Interest Entity, Primary Beneficiary [Member] | Consolidation, Eliminations [Member]
Summary Of Significant Accounting Policies [Line Items]
Total assets	31,987						31,987		$ 35,714
Total liabilities	2,216						2,216		$ 5,777
Total revenue	18,206			18,206			61,596	61,596
Comprehensive income loss	$ 3,698			$ 3,698			13,905	$ 13,905
Variable Interest Entity, Primary Beneficiary [Member] | CCACV JV LLC [Member]
Summary Of Significant Accounting Policies [Line Items]
Payment to acquire interest in joint venture							$ 2,940
Percentage of ownership interest in joint venture	49.00%						49.00%
Estimated additional total capital contributions necessary	$ 11,800						$ 11,800
Share of the net profit loss in the operations of joint venture	486						1,250
Equity method investment carrying value	$ 1,690						$ 1,690

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total Revenue	$ 62,551	$ 34,744	$ 184,833	$ 103,825
Platform Subscription [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	25,834	21,959	72,048	60,849
Visits [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	28,455	7,177	90,936	25,681
Others [Member]
Disaggregation of Revenue [Line Items]
Total Revenue	$ 8,262	$ 5,608	$ 21,849	$ 17,295

Revenue - Summary of Accounts R

Revenue - Summary of Accounts Receivable Allowance for Credit Loss (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Allowance for doubtful accounts, beginning of the period	$ 686	$ 396	$ 396
Provisions	1,236	$ 621	717
Write-offs	(589)		(427)
Allowance for doubtful accounts, end of the period	$ 1,333		$ 686

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Revenue From Contract With Customer Line Items [Line Items]
Contract liability revenue recognised	$ 43,656	$ 25,229	$ 61,775	$ 57,128
Transaction price allocated to remaining performance obligations	$ 170,168		$ 170,168		$ 162,230
Performance obligation percentage of transaction price to recognised in the next twelve months	45.00%		45.00%		45.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-12-31
Revenue From Contract With Customer Line Items [Line Items]
Revenue remaining performance obligation expected timing of satisfaction	3 years		3 years
Unbilled Revenues [Member]
Revenue From Contract With Customer Line Items [Line Items]
Unbilled accounts receivable	$ 3,294		$ 3,294		$ 1,622

Revenue - Summary of Contract w

Revenue - Summary of Contract with Customer Asset and Liability (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Revenue from Contract with Customer [Abstract]
Total deferred revenue, beginning of the period	$ 77,386	$ 93,299
Additions	56,825	85,167
Recognized	(72,407)	(101,080)
Total deferred revenue, end of the period	$ 61,804	$ 77,386

Revenue - Summary of Contract_2

Revenue - Summary of Contract with Customer Liability Current and Non Current (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Current deferred revenue	$ 54,324	$ 66,490
Non-current deferred revenue	7,480	10,896
Total deferred revenue, end of the period	$ 61,804	$ 77,386	$ 93,299

National Telehealth Network - A

National Telehealth Network - Additional Information (Detail) - NTN [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jan. 01, 2016
Schedule of Equity Method Investments [Line Items]
Income (loss) from equity method investments	$ (1,515)	$ 56	$ 3,920	$ 884
Noncontrolling Interest [Member]
Schedule of Equity Method Investments [Line Items]
Non controlling interest carrying value	$ 22,339		$ 22,339		$ 26,259
Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Business combination step acquisition equity interest in acquiree including subsequent acquisition percentage						100.00%
Minimum [Member]
Schedule of Equity Method Investments [Line Items]
Business combination step acquisition equity interest in acquiree including subsequent acquisition percentage						50.00%

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$ 182,869	$ 102,066
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	52,955	62,113
Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	129,914	39,953
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	52,955	62,113
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	52,955	62,113
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	129,914	39,953
Fair Value, Inputs, Level 2 [Member] | Investments [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	$ 129,914	$ 39,953

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Transfer from level one to level two fair value assets	$ 0
Transfer from level one to level three fair value assets	0
Transfer from level two to level one fair value assets	0
Transfer from level three to level one fair value assets	$ 0

Investments - Debt Securites, A

Investments - Debt Securites, Available-For-Sale (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 129,831	$ 39,355
Gross Unrealized Gains	83	598
Fair Value	129,914	39,953
U.S government securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	129,831	39,355
Gross Unrealized Gains	83	598
Fair Value	$ 129,914	$ 39,953

Business Combinations - Summary

Business Combinations - Summary of Final Allocation of Assets Acquired and Liabilities Assumed (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Goodwill	$ 193,877	$ 193,877	$ 127,268
Aligned Telehealth Inc [Member]
Business Acquisition [Line Items]
Cash	2,938
Accounts receivable	3,612
Identifiable intangible assets	14,100
Other assets	179
Total assets acquired	20,829
Current liabilities	(3,102)
Deferred tax liability	(1,388)
Total liabilities assumed	(4,490)
Goodwill	66,609
Total purchase consideration	$ 82,948

Business Combinations - Summa_2

Business Combinations - Summary of Identifiable Intangible Assets Acquired and Weighted Average Useful Lives (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Amount	$ 14,100
Customer relationships [Member] | Aligned Telehealth Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amount	$ 13,800
Weighted Average Life(Years)	7 years
Trade name [Member] | Aligned Telehealth Inc [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Amount	$ 300
Weighted Average Life(Years)	7 years

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - Aligned Telehealth Inc [Member] - USD ($)	Nov. 30, 2019	Nov. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Business Combination, Consideration Transferred			$ 82,948
Payment to acquire busineesses		$ 48,688,000
Business combination contingent consideration transferred	$ 10,000
Business combination contingent consideration payable	$ 70,000,000	70,000,000
Business combination acquisition costs expensed				$ 1,494,000
Series C Redeemable Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Business combination consideration in shares issued or issuable	456,667
Business combination equity interests issued or issuable	$ 34,250,000	$ 34,250,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Goodwill (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance as of January 1	$ 193,877	$ 127,268
Goodwill acquired (Note 7)		66,609
Ending Balance	$ 193,877	$ 193,877

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of finite lived Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 76,680	$ 76,680
Accumulated Amortization	(18,962)	(13,145)
Carrying Value	57,718	63,535
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	38,782	38,782
Accumulated Amortization	(10,390)	(7,416)
Carrying Value	$ 28,392	$ 31,366
Weighted Average Remaining Life	7 years 3 months 18 days	8 years
Contractor relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 535	$ 535
Accumulated Amortization	(195)	(165)
Carrying Value	$ 340	$ 370
Weighted Average Remaining Life	8 years 3 months 18 days	9 years
Trade name [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 300	$ 300
Accumulated Amortization	(38)	(4)
Carrying Value	$ 262	$ 296
Weighted Average Remaining Life	6 years 1 month 6 days	6 years 10 months 24 days
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	$ 37,063	$ 37,063
Accumulated Amortization	(8,339)	(5,560)
Carrying Value	$ 28,724	$ 31,503
Weighted Average Remaining Life	7 years 9 months 18 days	8 years 6 months

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets Future Amortization Expense (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
2020	$ 1,938
2021	7,755
2022	7,755
2023	7,755
2024	7,755
Thereafter	$ 24,760

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,940	$ 1,435	$ 5,817	$ 4,305

Accrued Expenses And Other Cu_3

Accrued Expenses And Other Current Liabilities - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Employee compensation, benefits, and payroll taxes	$ 18,133	$ 11,698
Professional services	3,805	3,351
Provider services	4,043	2,709
Transaction costs	2,518
Other	9,802	9,593
Total	$ 38,301	$ 27,351

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail) - USD ($)	Jan. 31, 2011	Sep. 30, 2020	Dec. 31, 2019	Nov. 30, 2017
Line of Credit Facility [Line Items]
Letter of credit outstanding		$ 1,095,000	$ 1,143,000
Two Thousand And Eleven Line Of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity	$ 5,000,000
Two Thousand And Eleven Line Of Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument varirable interest rate spread	1.25%
Two Thousand And Seventeen Amended Line Of Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit maximum borrowing capacity				$ 7,000,000
Line of credit net of current portion outstanding		0	0
Line of credit remaining borrowing capacity		$ 5,905,000	$ 5,857,000

Stockholders' Equity - Converti

Stockholders' Equity - Convertible Preferred Stock (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized	0	17,744,445
Shares Issued	0	14,061,508
Shares Outstanding	0	14,012,935
Liquidation Preference	$ 0	$ 608,449
Carrying Value		$ 655,799
Series A [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized		3,200,000
Shares Issued		3,178,650
Shares Outstanding		3,130,077
Liquidation Preference		$ 51,741
Carrying Value		$ 28,889
Series B [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized		833,334
Shares Issued		787,725
Shares Outstanding		787,725
Liquidation Preference		$ 37,060
Carrying Value		$ 23,632
Series C [Member]
Redeemable Noncontrolling Interest [Line Items]
Shares Authorized		13,711,111
Shares Issued		10,095,133
Shares Outstanding		10,095,133
Liquidation Preference		$ 519,648
Carrying Value		$ 603,278

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock (Detail) - shares	Sep. 30, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Shares Authorized	1,300,000,000
Shares Issued	235,637,199
Shares Outstanding	234,235,243
Class A [Member]
Class of Stock [Line Items]
Shares Authorized	1,000,000,000	1,000,000,000
Shares Issued	200,131,318	200,131,318
Shares Outstanding	199,647,646	199,647,646
Class B [Member]
Class of Stock [Line Items]
Shares Authorized	100,000,000	100,000,000
Shares Issued	29,950,326	29,950,326
Shares Outstanding	29,032,042	29,032,042
Class C [Member]
Class of Stock [Line Items]
Shares Authorized	200,000,000	200,000,000
Shares Issued	5,555,555	5,555,555
Shares Outstanding	5,555,555	5,555,555

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Common Stock (Parenthetical) (Detail)	Sep. 30, 2020$ / shares
Class A [Member]
Class of Stock [Line Items]
Common Stock, Par Value	$ 1,997
Class B [Member]
Class of Stock [Line Items]
Common Stock, Par Value	290
Class C [Member]
Class of Stock [Line Items]
Common Stock, Par Value	$ 56

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Share Based Compensation Arrangements By Share Based Payment Award (Detail) - 2020 Equity Incentive Plan [Member] $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning of period | shares	24,917,003
Granted | shares	2,637,220
Forfeited | shares	(1,697,171)
Expired | shares	(132,001)
Exercised | shares	(1,660,751)
Outstanding, end of period | shares	24,064,300	24,917,003
Vested and expected to vest | shares	22,212,804	22,650,355
Options exercisable | shares	16,254,829	14,685,654
Outstanding, beginning of period | $ / shares	$ 3.90
Granted | $ / shares	7.80
Forfeited | $ / shares	4.80
Expired | $ / shares	2.16
Exercised | $ / shares	2.59
Outstanding, end of period | $ / shares	4.35	$ 3.90
Vested and expected to vest, Weighted average exercise price | $ / shares	4.09	3.73
Options exercisable, Weighted average exercise price | $ / shares	$ 3.43	$ 2.83
Weighted average contractual term(Years)	6 years 4 months 24 days	6 years 10 months 24 days
Weighted average contractual term(Years)	6 years 2 months 12 days	6 years 8 months 12 days
Weighted average contractual term(Years)	5 years 3 months 18 days	5 years 6 months
Aggregate intrinsic value | $	$ 610,782	$ 79,798
Vested and expected to vest, Aggregate intrinsic value | $	567,533	76,321
Options exercisable, Aggregate intrinsic value | $	$ 426,049	$ 62,869

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Nonvested Restricted Stock Units Activity (Detail) - $ / shares	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2020
Class of Stock [Line Items]
Granted	2,860,880
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Unvested as of December 31, 2019		2,322,408
Granted		13,039,392
Vested		(3,810,645)
Forfeited		(3,871)
Unvested as of September 30, 2020		11,547,284
Unvested as of December 31, 2019		$ 5.79
Granted		13.41
Vested		9.50
Forfeited		10.79
Unvested as of September 30, 2020		$ 13.17

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Share Based Payment Award Stock Options Valuation Assumptions (Detail)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Risk-free interest rate	1.09%	2.44%
Expected term (in years)	6 years 1 month 6 days	6 years 1 month 6 days
Expected volatility	52.00%	50.00%
Expected dividend yield	0.00%	0.00%

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Employee Service Share Based Compensation Allocation Of Recognized Period Costs (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 34,420	$ 3,604	$ 106,516	$ 8,675
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	309	124	668	360
Research and development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	2,083	360	3,519	1,169
Selling and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	1,138	540	2,684	1,848
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expenses	$ 30,890	$ 2,580	$ 99,645	$ 5,298

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Sep. 21, 2020	Aug. 22, 2020	May 31, 2020	Feb. 29, 2020	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Aug. 17, 2020
Temporary Equity [Line Items]
Preferred stock authorized					100,000,000			100,000,000		0
Preferred stock per share					$ 0.01			$ 0.01		$ 0.01
Common stock authorized					1,300,000,000			1,300,000,000
Stock-based compensation expenses					$ 34,420		$ 3,604	$ 106,516	$ 8,675
Common stock reserve for issuance					63,226,337			63,226,337		157,998,948
Restricted stock units						2,860,880
Underwriting discounts and commissions								$ 49,336,000
Common stock issued					27,614,753			27,614,753
Expected Volatility Rate								(52.00%)	(50.00%)
Stock Issued During Period Value For Private Placement					$ 99,100,000
Sharebased Payment Arrangement Adjustment for Tax Withholding Obligation					24,157,000
IPO [Member]
Temporary Equity [Line Items]
Sharebased Payment Arrangement Adjustment for Tax Withholding Obligation								$ 24,157,000
Restricted Stock [Member]
Temporary Equity [Line Items]
Unrecognized stock-based compensation					39,449,000			$ 39,449,000
Restricted stock units								13,039,392		2,616,345
weighted-average period								3 years
Stock based compensation expected to vest					$ 31,253,000		$ 1,297,000	$ 91,168,000	$ 1,297,000
Restricted Stock [Member] | Minimum [Member]
Temporary Equity [Line Items]
Award Requisite Service Period								3 years		2 years
Restricted Stock [Member] | Maximum [Member]
Temporary Equity [Line Items]
Award Requisite Service Period								4 years		4 years
2020 Equity Incentive Plan [Member]
Temporary Equity [Line Items]
Weighted-average grant date fair value of common stock					$ 5.06		$ 0	$ 4.17	$ 2.78
Unrecognized stock-based compensation					$ 12,688,000			$ 12,688,000
weighted-average period								2 years 7 months 13 days
Common stock, capital shares addition reserved for future issuance											3,710,240
2020 Equity Incentive Plan [Member] | IPO [Member]
Temporary Equity [Line Items]
Common stock reserve for issuance											31,275,204
2020 Employee Stock Purchase Plan [member]
Temporary Equity [Line Items]
Common stock reserve for issuance					3,084,218			3,084,218
Share-based compensation arrangement by share-based payment award, maximum employee subscription amount					$ 25,000,000			$ 25,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date								85.00%
Executive Equity Awards [Member]
Temporary Equity [Line Items]
Share-based payment arrangement, accelerated cost						$ 5,659,000
Expected stock based compensation								$ 23,644,000
Executive Equity Awards [Member] | Chief Executive Officer [Member]
Temporary Equity [Line Items]
Stock options modified to accelerate the vesting and to eliminate the future service period						1,764,884
Executive Equity Awards [Member] | Restricted Stock [Member] | Chief Executive Officer [Member]
Temporary Equity [Line Items]
Stock-based compensation expenses						$ 56,971,000
Restricted stock units						5,721,760
Number of restricted stock units issued								3,230,750
Share Based Payment Award Percentage Of Outstanding Stock Maximum								1.50%
Share Price					$ 9.96			$ 9.96
Expected Volatility Rate								(60.00%)
Executive Equity Awards [Member] | Restricted Stock [Member] | Chief Executive Officer Two [Member]
Temporary Equity [Line Items]
Restricted stock units						2,860,880
Executive Equity Awards [Member] | Restricted Stock [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]
Temporary Equity [Line Items]
Percentage of fully-diluted outstanding capital stock								50.00%
Share Based Payment Award Percentage Of Outstanding Stock Maximum								0.75%
Executive Equity Awards [Member] | Restricted Stock [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]
Temporary Equity [Line Items]
Percentage of fully-diluted outstanding capital stock								50.00%
Share Based Payment Award Percentage Of Outstanding Stock Maximum								0.75%
Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Convertible preferred stock then outstanding					15,525,685			15,525,685
Value of convertible preferred stock					$ 801,813,000			$ 801,813,000
Common Class A [Member]
Temporary Equity [Line Items]
Number of new stock issued								45,681,499
Common stock per share					$ 18			$ 18
Deffered offering cost					$ 4,394,000			$ 4,394,000
Common stock authorized					1,000,000,000			1,000,000,000		1,000,000,000
Common stock per share					$ 0.01			$ 0.01		$ 0.01
Shares of common stock pursuant to the exercise of options								4,459,277
Sale of Stock, Consideration Received on Transaction								$ 768,537,000
Common Class A [Member] | IPO [Member]
Temporary Equity [Line Items]
Convertible preferred stock then outstanding	136,625,900
Shares issued, price per share	$ 18
Number of new stock issued	45,681,499
Underwriting discounts and commissions	$ 49,336,000
Sale of Stock, Consideration Received on Transaction	$ 768,537,000
Common Class B [Member]
Temporary Equity [Line Items]
Common stock authorized					100,000,000			100,000,000		100,000,000
Common stock per share					$ 0.01			$ 0.01		$ 0.01
Common stock, voting rights								(x) 1.0408163 and (y) the total number of votes that would be cast at such time by the holders of the Class A and Class C common stock and any other preferred stock entitled to vote under the certificate of incorporation at such time (resulting in the Class B common stock collectively holding 51% of the total outstanding voting power)
Common Class C [Member]
Temporary Equity [Line Items]
Number of new stock issued								5,555,555
Common stock authorized					200,000,000			200,000,000		200,000,000
Common stock per share					$ 0.01			$ 0.01		$ 0.01
Stock Issued During Period Value For Private Placement		$ 100,000						$ 99,100,000
Payments of Stock Issuance Costs		$ 900,000			$ 900,000			$ 900,000
Preferred Stock [Member]
Temporary Equity [Line Items]
Preferred stock authorized					100,000,000			100,000,000
Preferred stock per share					$ 0.01			$ 0.01
Series C Preferred Stock [Member]
Temporary Equity [Line Items]
Shares issued, price per share			$ 100	$ 75						$ 75
Number of new stock issued			1,342,750	170,000						628,719
Proceeds from stock issuance			$ 134,275,000	$ 12,750,000						$ 47,154,000
Issurance cost			$ 750,000	$ 261,000						$ 1,318,000
Stock issued during period, shares, acquisitions										456,667
Common Stock Class A And Class B [Member] | IPO [Member]
Temporary Equity [Line Items]
Sharebased Payment Arrangement Shares Withheld for Tax Withholding Obligations								1,340,354
Common Stock Class A And Class B [Member] | 2020 Equity Incentive Plan [Member]
Temporary Equity [Line Items]
Common stock reserve for issuance											22,083,184

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Pending Litigation [Member]
Loss Contingencies [Line Items]
Pending Claims Number	0	0
Indemnification Agreement [Member]
Loss Contingencies [Line Items]
New Claims Filed, Number	0	0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 78	$ (392)	$ 330	$ (22)

Related-Party Transactions - Ad

Related-Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Short-term deferred revenue	$ 54,324		$ 54,324		$ 66,490
Long-term deferred revenue	7,480		7,480		10,896
Revenues recognized from related party			(72,407)		(101,080)
Payment to acquire interest in joint venture			2,940
Short-term and long-term deferred revenue	61,804		61,804		77,386	$ 93,299
Payment to executive officers for stock tax loans			16,441
Teva Pharmaceuticals Industries Ltd [Member]
Related Party Transaction [Line Items]
Short-term deferred revenue	0		0		0
Long-term deferred revenue	0		0		0
Due from related parties	0		0		0
Philips Holding USA Inc [Member]
Related Party Transaction [Line Items]
Short-term deferred revenue	1,195		1,195		2,549
Long-term deferred revenue	1,195		1,195		2,549
Due from related parties	0		0		0
Revenues recognized from related party	418	$ 146	1,126	$ 372
Anthem Inc [Member]
Related Party Transaction [Line Items]
Short-term deferred revenue	4,671		4,671		11,561
Long-term deferred revenue	4,671		4,671		11,561
Due from related parties	1,178		1,178		2,499
Revenues recognized from related party	13,522	7,837	40,677	23,120
Cleveland Clinic [Member]
Related Party Transaction [Line Items]
Short-term deferred revenue	457		457		180
Long-term deferred revenue	457		457		180
Due from related parties	205		205		0
Revenues recognized from related party	514	$ 262	1,004	$ 889
CCAW JV LLC [Member]
Related Party Transaction [Line Items]
Due from related parties	0		0
Revenues recognized from related party	$ 404		$ 1,190
Equity Method Investment, Ownership Percentage	50.00%		50.00%
Payment to acquire interest in joint venture			$ 2,940
Short-term and long-term deferred revenue	$ 277		$ 277
CFO and Other Executive Officers [Member]
Related Party Transaction [Line Items]
Promissory notes with chief financial officer					$ 1,781

Net Loss per Share - Schedule o

Net Loss per Share - Schedule of Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator:
Net loss	$ (64,596)	$ (88,219)	$ (25,225)	$ (24,071)	$ (20,057)	$ (21,515)	$ (178,040)	$ (65,643)
Net income (loss) attributable to non-controlling interest	(1,515)			(56)			(3,920)	(884)
Net loss attributable to American Well Corporation	$ (63,081)			$ (24,015)			$ (174,120)	$ (64,759)
Denominator:
Weighted-average common shares outstanding—basic and diluted	68,499,106			41,933,597			51,492,988	41,805,929
Net loss per share attributable to common stockholders—basic and diluted	$ (0.92)			$ (0.57)			$ (3.38)	$ (1.55)

Net Loss per Share - Schedule_2

Net Loss per Share - Schedule of Antidilutive Securities Excluded From Computation of Earning Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	29,519,954	137,475,287	29,519,954	137,475,287
Convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		113,762,320		113,762,320
Unvested restricted stock units Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	5,455,654		5,455,654
Options to purchase shares of common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	24,064,300	23,712,967	24,064,300	23,712,967